Prosecution Insights
Last updated: May 29, 2026

Glycomimetics Inc.

4 pending office actions • 1 art units • 4 examiners • 4 of 4 (100%) have an AI response strategy ready

Portfolio Summary

4
Total Pending OAs
2
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (25%)
1
Easy (25%)
2
Unknown (50%)

Rejection Statute Mix

BucketCases
§103 only1 (25%)
§112 only1 (25%)
No statute on record2 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KRISHNAN, GANAPATHY 1 52.2% +0.0%
LEE, HOI YAN NMN 1 43.1% +77.9%
CHO, DAVID H 1 38.2% +75.0%
GALSTER, SAMUEL LEONARD 1 53.8% +39.1%

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
17597910 USE OF E-SELECTIN ANTAGONISTS TO ENHANCE THE SURVIVAL OF RECONSTITUTED, BONE MARROW-DEPLETED HOSTS GALSTER, SAMUEL LEONARD 120d overdue
17998942 COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS CHO, DAVID H 4d overdue
18001614 COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING LEE, HOI YAN NMN 21d

Top Art Units

Art UnitApps
1693 4

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18546609 PROCESS FOR PREPARING AN E-SELECTIN INHIBITOR INTERMEDIATE KRISHNAN, GANAPATHY 1693 §112 Non-Final OA 60d overdue AI Ready Aug 16, 2023
18001614 COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING LEE, HOI YAN NMN 1693 Other Final Rejection 21d AI Ready Dec 13, 2022
17998942 COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS CHO, DAVID H 1693 Other Final Rejection 4d overdue AI Ready Nov 16, 2022
17597910 USE OF E-SELECTIN ANTAGONISTS TO ENHANCE THE SURVIVAL OF RECONSTITUTED, BONE MARROW-DEPLETED HOSTS GALSTER, SAMUEL LEONARD 1693 §103 Non-Final OA 120d overdue AI Ready Jan 28, 2022

Managing Glycomimetics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month